FIELD: medicine.
SUBSTANCE: method involves quantitatively determining C-reactive protein, medium molecular mass peptides and lactoferrine levels in blood. C-reactive protein marker growing 5 times as high and higher, medium molecular mass peptides level increment becoming equal to or greater than 25% relative to reference value, and lactoferrine level being greater than 1400 ng/ml within the first 24-72 h after clinical symptoms of inflammatory system response syndrome manifestations being observed, mesenchymal sepsis diagnosis is to be set.
EFFECT: high reliability in setting mesenchymal sepsis diagnosis.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ESTIMATING MESENCHYMAL SEPSIS INTENSIVE CARE EFFECTIVENESS | 2006 |
|
RU2322678C1 |
| METHOD OF PREDICTION OF DEVELOPING SUPPURATIVE COMPLICATIONS OF PANCREATONECROSIS AT EARLY STAGES OF DISEASE | 2015 |
|
RU2605851C1 |
| METHOD FOR DETERMINING THE TYPE OF INFECTIOUS AND ASEPTIC PARAPROSTHETIC/PARAIMPLANT POSTOPERATIVE COMPLICATIONS FOLLOWING PROSTHETIC REPAIR OF LARGE JOINTS | 2020 |
|
RU2766803C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF STERILE AND INFECTED PANCREATITIS | 2022 |
|
RU2793647C1 |
| METHOD FOR PROGRAMMED IRRIGATION-ASPIRATION SANATION IN PURULO-NECROTIC COMPLICATIONS OF DIABETIC FOOT INFECTIONS | 2013 |
|
RU2539165C1 |
| METHOD OF PREDICTING DEVELOPMENT OF GENERALISED COMPLICATIONS IN CASE OF ACUTE DESTRUCTIVE PANCREATITIS | 2008 |
|
RU2393771C1 |
| METHOD FOR COMBINED TREATMENT OF III-IV DEGREE CHRONIC ARTERIAL INSUFFICIENCY OF LOWER EXTREMITIES | 2018 |
|
RU2718287C1 |
| DIAGNOSING OF CLINICAL COURSE OF PANCREATONECROSIS | 2011 |
|
RU2463601C1 |
| METHOD FOR LABORATORY ASSESSMENT OF EFFICACY OF ANTIBACTERIAL THERAPY | 2012 |
|
RU2543335C2 |
| METHOD OF REPLACEMENT SELENOTHERAPY IN SEPTIC ENCEPHALOPATHY | 2023 |
|
RU2802154C1 |
